Af­ter land­ing funds from Roy­al­ty, Cy­to­ki­net­ics an­nounces afi­camten PhII re­sults; Pol­ish CRO Selvi­ta re­struc­tures in search for new growth

Cal­i­for­nia-based Cy­to­ki­net­ics an­nounced that pos­i­tive re­sults from a Phase II tri­al of afi­camten showed pos­i­tive re­sults in pa­tients bat­tling hy­per­trophic car­diomy­opa­thy.

The third co­hort of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER